Cargando…

Immune and genomic biomarkers of immunotherapy response in cancer of unknown primary

BACKGROUND: Cancer of unknown primary (CUP) is a heterogeneous group of metastatic cancers where a primary tissue of origin (TOO) is uncertain. Most patients with CUP have limited treatment options and poor survival outcomes. Immune checkpoint inhibitors (ICIs) can be efficacious in some patients wi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Posner, Atara, Sivakumaran, Tharani, Pattison, Andrew, Etemadmoghadam, Dariush, Thio, Niko, Wood, Colin, Fisher, Krista, Webb, Samantha, DeFazio, Anna, Wilcken, Nicholas, Gao, Bo, Karapetis, Christos S, Singh, Madhu, Collins, Ian M, Richardson, Gary, Steer, Christopher, Warren, Mark, Karanth, Narayan, Fellowes, Andrew, Fox, Stephen B, Hicks, Rodney J, Schofield, Penelope, Bowtell, David, Prall, Owen W J, Tothill, Richard William, Mileshkin, Linda
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2023
Materias:	Immunotherapy Biomarkers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10098268/ https://www.ncbi.nlm.nih.gov/pubmed/36720497 http://dx.doi.org/10.1136/jitc-2022-005809

Ejemplares similares

A comparison of DNA sequencing and gene expression profiling to assist tissue of origin diagnosis in cancer of unknown primary
por: Posner, Atara, et al.
Publicado: (2022)

Uncertainty and the unmet informational needs of patients with cancer of unknown primary (CUP): a cross-sectional multi-site study
por: Guccione, Lisa, et al.
Publicado: (2022)

Early tumor shrinkage identifies long-term disease control and survival in patients with lung cancer treated with atezolizumab
por: Hopkins, Ashley M, et al.
Publicado: (2020)

Clinical, FDG-PET and molecular markers of immune checkpoint inhibitor response in patients with metastatic Merkel cell carcinoma
por: Weppler, Alison M, et al.
Publicado: (2020)

Patients with HIV-associated cancers have evidence of increased T cell dysfunction and exhaustion prior to cancer diagnosis
por: Chaudhary, Omkar, et al.
Publicado: (2022)

Six-year experience of Australia’s first dedicated cancer of unknown primary clinic
por: van Mourik, Arielle, et al.
Publicado: (2023)

Multiparametric MRI of early tumor response to immune checkpoint blockade in metastatic melanoma
por: Lau, Doreen, et al.
Publicado: (2021)

Pan-cancer landscape of CD274 (PD-L1) rearrangements in 283,050 patient samples, its correlation with PD-L1 protein expression, and immunotherapy response
por: Kelly, Andrew D, et al.
Publicado: (2021)

Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors
por: Cristescu, Razvan, et al.
Publicado: (2022)

Single-cell analysis reveals clonally expanded tumor-associated CD57(+) CD8 T cells are enriched in the periphery of patients with metastatic urothelial cancer responding to PD-L1 blockade
por: Fehlings, Michael, et al.
Publicado: (2022)

LRP1B mutations are associated with favorable outcomes to immune checkpoint inhibitors across multiple cancer types
por: Brown, Landon C, et al.
Publicado: (2021)

Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma
por: Haddad, Robert I, et al.
Publicado: (2022)

Higher proportions of CD39+ tumor-resident cytotoxic T cells predict recurrence-free survival in patients with stage III melanoma treated with adjuvant immunotherapy
por: Attrill, Grace Heloise, et al.
Publicado: (2022)

Nivolumab serum concentration in metastatic melanoma patients could be related to outcome and enhanced immune activity: a gene profiling retrospective analysis
por: Mallardo, Domenico, et al.
Publicado: (2022)

Prognostic significance of myeloid immune cells and their spatial distribution in the colorectal cancer microenvironment
por: Väyrynen, Juha P, et al.
Publicado: (2021)

Plasma IL-6 changes correlate to PD-1 inhibitor responses in NSCLC
por: Keegan, Alissa, et al.
Publicado: (2020)

Gene signature of antigen processing and presentation machinery predicts response to checkpoint blockade in non-small cell lung cancer (NSCLC) and melanoma
por: Thompson, Jeffrey C, et al.
Publicado: (2020)

Novel, non-invasive imaging approach to identify patients with advanced non-small cell lung cancer at risk of hyperprogressive disease with immune checkpoint blockade
por: Vaidya, Pranjal, et al.
Publicado: (2020)

KALRN mutations promote antitumor immunity and immunotherapy response in cancer
por: Li, Mengyuan, et al.
Publicado: (2020)

Identification of FABP5 as an immunometabolic marker in human hepatocellular carcinoma
por: Liu, Fangming, et al.
Publicado: (2020)

Development and validation of a genomic mutation signature to predict response to PD-1 inhibitors in non-squamous NSCLC: a multicohort study
por: Bai, Xue, et al.
Publicado: (2020)

Predicting response to immunotherapy in advanced non-small-cell lung cancer using tumor mutational burden radiomic biomarker
por: He, Bingxi, et al.
Publicado: (2020)

Nectin4 is a novel TIGIT ligand which combines checkpoint inhibition and tumor specificity
por: Reches, Adi, et al.
Publicado: (2020)

Correlates of clinical benefit from immunotherapy and targeted therapy in metastatic renal cell carcinoma: comprehensive genomic and transcriptomic analysis
por: Dizman, Nazli, et al.
Publicado: (2020)

Baseline metabolic tumor volume as a strong predictive and prognostic biomarker in patients with non-small cell lung cancer treated with PD1 inhibitors: a prospective study
por: Chardin, David, et al.
Publicado: (2020)

Galectin-9-based immune risk score model helps to predict relapse in stage I–III small cell lung cancer
por: Chen, Peixin, et al.
Publicado: (2020)

Intratumoral injection reduces toxicity and antibody-mediated neutralization of immunocytokine in a mouse melanoma model
por: Baniel, Claire C, et al.
Publicado: (2020)

Prognostic value of novel immune-related genomic biomarkers identified in head and neck squamous cell carcinoma
por: Yao, Yao, et al.
Publicado: (2020)

Impact of body composition on outcomes from anti-PD1 +/− anti-CTLA-4 treatment in melanoma
por: Young, Arissa C, et al.
Publicado: (2020)

Prediction of immune checkpoint inhibition with immune oncology-related gene expression in gastrointestinal cancer using a machine learning classifier
por: Lu, Zhihao, et al.
Publicado: (2020)

Tumor copy-number alterations predict response to immune-checkpoint-blockade in gastrointestinal cancer
por: Lu, Zhihao, et al.
Publicado: (2020)

Efficacy of immunotherapy in lung cancer with co-occurring mutations in NOTCH and homologous repair genes
por: Mazzotta, Marco, et al.
Publicado: (2020)

Is there a link between very early changes of primary and secondary lymphoid organs in (18)F-FDG-PET/MRI and treatment response to checkpoint inhibitor therapy?
por: Seith, Ferdinand, et al.
Publicado: (2020)

Discovery and validation of surface N-glycoproteins in MM cell lines and patient samples uncovers immunotherapy targets
por: Oldham, Robyn A A, et al.
Publicado: (2020)

M2-like macrophages dictate clinically relevant immunosuppression in metastatic ovarian cancer
por: Hensler, Michal, et al.
Publicado: (2020)

Distinctive germline expression of class I human leukocyte antigen (HLA) alleles and DRB1 heterozygosis predict the outcome of patients with non-small cell lung cancer receiving PD-1/PD-L1 immune checkpoint blockade
por: Correale, Pierpaolo, et al.
Publicado: (2020)

Stromal LAG-3(+) cells infiltration defines poor prognosis subtype muscle-invasive bladder cancer with immunoevasive contexture
por: Zeng, Han, et al.
Publicado: (2020)

MRI of tumor T cell infiltration in response to checkpoint inhibitor therapy
por: Jiang, Xiaoyu, et al.
Publicado: (2020)

Expression and clinical significance of PD-L1, B7-H3, B7-H4 and VISTA in craniopharyngioma
por: Wang, Yuelong, et al.
Publicado: (2020)

Differential expansion of circulating human MDSC subsets in patients with cancer, infection and inflammation
por: Cassetta, Luca, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_pi5rse5igvhs4pvehp9jvhj05l